We are live on ! Find out more
RCM

RA Capital Management Portfolio holdings

AUM $9.44B
1-Year Est. Return 157.3%
This Fund
S&P 500
This Quarter Est. Return
+29.99%
1 Year Est. Return
+157.3%
3 Year Est. Return
+589.39%
5 Year Est. Return
+654.96%
10 Year Est. Return
+50,915.53%
AUM
$815M
AUM Growth
+$109M
Cap. Flow
-$5.4M
Cap. Flow %
-0.66%
Top 10 Hldgs %
85.95%
Holding
32
New
5
Increased
2
Reduced
5
Closed
8

Top Buys

Rank Stock Value
1
ESPR
Esperion Therapeutics
ESPR
+$16.1M
2
LOXO
Loxo Oncology, Inc
LOXO
+$12.3M
3
ACOR
Acorda Therapeutics
ACOR
+$11.7M
4
MYOV
Myovant Sciences Ltd.
MYOV
+$9.73M
5
RXDX
Ignyta, Inc.
RXDX
+$7.49M

Top Sells

Rank Stock Value
1
AVXS
AveXis, Inc. Common Stock
AVXS
+$16.4M
2
ARDX icon
Ardelyx
ARDX
+$14.6M
3
AIMT
Aimmune Therapeutics
AIMT
+$13.9M
4
ABEO icon
Abeona Therapeutics
ABEO
+$5.54M
5
SBBP
Strongbridge Biopharma plc.
SBBP
+$5.47M

Sector Composition

Rank Sector Weight
1 Healthcare 97.48%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
WVE icon
1
Wave Life Sciences
WVE
$1.12B
$195M 23.91%
7,088,651
– –
ASND icon
2
Ascendis Pharma A/S
ASND
$16.5B
$151M 18.58%
5,409,990
– –
AVXS
3
DELISTED
AveXis, Inc. Common Stock
AVXS
$124M 15.16%
1,625,211
-265,585
-14% -$16.4M
ACHN
4
DELISTED
Achillion Pharmaceuticals
ACHN
$57.4M 7.04%
13,633,220
– –
NGNE icon
5
Neurogene
NGNE
$672M
$36.2M 4.44%
109,202
-397
-0.4% -$139K
BCRX icon
6
BioCryst Pharmaceuticals
BCRX
$2.42B
$29.3M 3.6%
3,489,795
+500,000
+17% +$3.48M
RARX
7
DELISTED
Ra Pharmaceuticals, Inc. Common Stock
RARX
$28.8M 3.53%
1,351,808
– –
MYOV
8
DELISTED
Myovant Sciences Ltd.
MYOV
$27.6M 3.38%
2,348,422
+848,422
+57% +$9.73M
ZGNX
9
DELISTED
Zogenix, Inc.
ZGNX
$26.6M 3.26%
2,451,237
– –
ESPR
10
DELISTED
Esperion Therapeutics
ESPR
$24.9M 3.05%
+704,701
New +$16.1M
LOXO
11
DELISTED
Loxo Oncology, Inc
LOXO
$12.6M 1.54%
+298,935
New +$12.3M
ARDX icon
12
Ardelyx
ARDX
$1.24B
$10.5M 1.29%
828,283
-1,107,022
-57% -$14.6M
ACOR
13
DELISTED
Acorda Therapeutics
ACOR
$10.3M 1.26%
+4,082
New +$11.7M
BOLD
14
DELISTED
Audentes Therapeutics, Inc
BOLD
$9.07M 1.11%
532,426
– –
FOMX
15
DELISTED
Foamix Pharmaceuticals Ltd. Ordinary Shares
FOMX
$9.01M 1.11%
1,820,138
– –
RXDX
16
DELISTED
Ignyta, Inc.
RXDX
$8.82M 1.08%
+1,025,291
New +$7.49M
ONC
17
BeOne Medicines Ltd
ONC
$33.9B
$8.79M 1.08%
240,000
– –
CALA
18
DELISTED
Calithera Biosciences, Inc
CALA
$8.37M 1.03%
+36,250
New +$6.26M
DRNA
19
DELISTED
Dicerna Pharmaceuticals, Inc.
DRNA
$8.26M 1.01%
2,428,571
– –
TGTX icon
20
TG Therapeutics
TGTX
$8.19B
$8.15M 1%
700,000
-304,314
-30% -$2.18M
PTGX icon
21
Protagonist Therapeutics
PTGX
$8.55B
$8.15M 1%
636,248
-56,315
-8% -$908K
KALV
22
DELISTED
KalVista Pharmaceuticals
KALV
$4.62M 0.57%
591,070
– –
EIGR
23
DELISTED
Eiger BioPharmaceuticals, Inc.
EIGR
$4.06M 0.5%
11,807
– –
MDCO
24
DELISTED
Medicines Co
MDCO
$3.91M 0.48%
79,899
– –
ABEO icon
25
Abeona Therapeutics
ABEO
$355M
– –
-45,714
Closed -$5.54M
1
2

Similar funds

RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
SCM
SCS Capital Management Boston, Massachusetts $9.44B AUM 18.1% 1-Year Est. Return
SIM
SRS Investment Management New York $9.47B AUM 60.12% 1-Year Est. Return
NPT
National Philanthropic Trust Jenkintown, Pennsylvania $9.38B AUM 33.37% 1-Year Est. Return
AC
Allstate Corporation Northbrook, Illinois $9.35B AUM 16.13% 1-Year Est. Return
PVI
Partners Value Investments Hamilton, Bermuda $9.34B AUM 12.2% 1-Year Est. Return
WPL
WINDACRE PARTNERSHIP LLC Houston, Texas $9.34B AUM 17.41% 1-Year Est. Return
BAMF
BI Asset Management Fondsmaeglerselskab Kobenhavn, Denmark $9.55B AUM 31.94% 1-Year Est. Return

RA Capital Management's Q1 2017 Portfolio in Review

As of Q1 2017, RA Capital Management held 32 positions worth $815M, up 16% from $706M the previous quarter. Its ten largest holdings account for 86% of the portfolio.

RA Capital Management's Q1 2017 filing shows 5 new, 2 increased, 5 reduced and 8 closed positions. Its largest new stake was Esperion Therapeutics: 704,701 shares worth $24.9M. The largest sale was AveXis, Inc. Common Stock, an estimated $16.4M.

By sector, the portfolio is most concentrated in Healthcare at 97% of assets, up from 97% a quarter earlier.

  • RA Capital Management's largest Q1 2017 buy was Esperion Therapeutics: 704,701 shares worth $24.9M.
  • RA Capital Management added most to Myovant Sciences Ltd. in Q1 2017, an estimated $9.73M increase.
  • RA Capital Management's biggest Q1 2017 reduction was AveXis, Inc. Common Stock, cutting an estimated $16.4M.
  • RA Capital Management fully exited Aimmune Therapeutics in Q1 2017, selling an estimated $13.9M.
  • RA Capital Management's ten largest holdings make up 86% of its $815M portfolio in Q1 2017.
  • RA Capital Management opened 5 new positions and closed 8 in Q1 2017.
  • RA Capital Management's portfolio value rose 16% quarter-over-quarter to $815M.

Based on RA Capital Management's 13F filing for Q1 2017, filed 15 May 2017.